JPH10504819A - アンチセンスおよびトリプレックス治療薬および方法 - Google Patents

アンチセンスおよびトリプレックス治療薬および方法

Info

Publication number
JPH10504819A
JPH10504819A JP8507452A JP50745296A JPH10504819A JP H10504819 A JPH10504819 A JP H10504819A JP 8507452 A JP8507452 A JP 8507452A JP 50745296 A JP50745296 A JP 50745296A JP H10504819 A JPH10504819 A JP H10504819A
Authority
JP
Japan
Prior art keywords
target
compound according
intercalator
sequence
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8507452A
Other languages
English (en)
Japanese (ja)
Inventor
オルトマン、シドニー
フィードラー、ポール
リヴァイン、ロバート・エイ
ワードロー、スティーヴン・シー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPH10504819A publication Critical patent/JPH10504819A/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/15Nucleic acids forming more than 2 strands, e.g. TFOs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3511Conjugate intercalating or cleaving agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP8507452A 1994-08-10 1995-08-09 アンチセンスおよびトリプレックス治療薬および方法 Pending JPH10504819A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28859394A 1994-08-10 1994-08-10
US38949695A 1995-02-16 1995-02-16
US08/389,496 1995-02-16
US08/288,593 1995-02-16
PCT/US1995/010055 WO1996004788A1 (fr) 1994-08-10 1995-08-09 Agents et procedes de therapies antisens et triplex

Publications (1)

Publication Number Publication Date
JPH10504819A true JPH10504819A (ja) 1998-05-12

Family

ID=26965112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8507452A Pending JPH10504819A (ja) 1994-08-10 1995-08-09 アンチセンスおよびトリプレックス治療薬および方法

Country Status (4)

Country Link
EP (1) EP0774902A1 (fr)
JP (1) JPH10504819A (fr)
CA (1) CA2197117A1 (fr)
WO (1) WO1996004788A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
SI1888748T1 (sl) 2005-05-25 2014-02-28 Tina Holding Aps Stabilna in selektivna formacija hoogsteen-tipa tripleksov in dupleksov, ki uporabljajo zvite interkalatne nukleinske kisline (TINA) in postopek za pripravo TINA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2540122B1 (fr) * 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides

Also Published As

Publication number Publication date
WO1996004788A1 (fr) 1996-02-22
MX9700991A (es) 1998-05-31
CA2197117A1 (fr) 1996-02-22
EP0774902A1 (fr) 1997-05-28

Similar Documents

Publication Publication Date Title
CA1322723C (fr) Inhibiteurs de la replication de retrovirus et de l'expression de produits oncogenes
EP0714436B1 (fr) Oligonucleotides actifs contre le virus de l'immunodeficience humaine
DE68925278T2 (de) Hemmung von htlv-iii durch exogene oligonukleotide
Rappaport et al. Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy
US5225337A (en) Ribozyme compositions and methods for use
US8962582B2 (en) PKR activation via hybridization chain reaction
CA2229171C (fr) Procede de modulation de l'expression d'un gene provoquant une reponse immunostimulatrice reduite
JP2021500025A (ja) B型肝炎感染の治療方法
JPH06508022A (ja) 生体分子に特異的なアプタマーおよび生産方法
JP3307944B2 (ja) ヒト・免疫不全ウイルスの増殖阻害化合物および方法
AU689129B2 (en) Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens
US20010010899A1 (en) Hpv-specific oligonucleotides
DE69611368T2 (de) Oligonukleotide spezifisch für humane papillomaviren
JPH10504819A (ja) アンチセンスおよびトリプレックス治療薬および方法
JP2022518808A (ja) レーバー先天黒内障の処置のためのアンチセンスオリゴヌクレオチド
CA2211877A1 (fr) Inhibiteurs de la transcription du virus de l'immunodeficience humaine et procedes pour les utiliser
MXPA97000991A (es) Agentes y metodos terapeuticos antisentido y triples
US6521601B1 (en) Method and composition for inhibition of viral replication
EP4587572A2 (fr) Produits et compositions
AU9825398A (en) Method and reagent for inhibiting human immunodeficiency virus replication